Bedaquiline (Sirturo) tablets: Potential supply issue

Supply issue Active

Due to unusual ordering patterns, there is a potential supply issue affecting bedaquiline tablets (Pharmacode 2659956), which treats multiple drug resistant tuberculosis.

9 May 2024 Update

The supplier has found an alternative. This product has now received provisional approval from Medsafe and is listed in the HML. 

Stock is expected to arrive by the end of May 2024.

Affected product

We are advised that there has been a significant increase of orders for bedaquiline tablets. The usual demand of bedaquiline tablets is 4-5 packs per month, this has trebled in recent months. 

Note this only relates to orders for the tablets. Multiple drug resistant tuberculosis (MDR-TB) is a notifiable disease. Pharmac is not aware of an increase in the number of reported cases of MDR-TB. 

  • Chemical: Bedaquiline
  • Presentation: Tab 100mg
  • Brand: Sirturo
  • Pharmacode: 2659956 
  • Subsidy: $3084.51
  • Measure / Qty: per 24 OP

Pharmac understands that availability of bedaquiline tablets varies by location.  

What is being done to address the issue

The supplier has found an alternate which has received provisional Medsafe approval. Stock is on order. Some stock remains available with the supplier.

The alternative has been listed in the HML(external link).

About bedaquiline

Bedaquiline is used to treat multidrug resistant tuberculosis (MDR-TB), it prevents the growth of tuberculosis in the body. It is used in people who have already been treated with other medicines that did not work well. We understand the importance of having this medicine available. 

Who to contact

If you or your whānau are affected by this supply issue, talk to the person who prescribed your bedaquiline.

If you have any other questions, email

Please include as much information as you can about the product (presentation, brand, pharmacode) and who your wholesaler is.

Sign up to our email list for regular emails about supply issues and more(external link)